Conversion therapy and R0 resection for pancreatic cancer with multiple liver metastases: a case report.

IF 2.7 3区医学 Q3 ONCOLOGY

Journal of Cancer Research and Clinical Oncology Pub Date : 2025-07-03 DOI:10.1007/s00432-025-06180-3

Sifan Dong, Yunlong Gao, Zhe Wang, Jinqiang Liang, An Jiang

{"title":"Conversion therapy and R0 resection for pancreatic cancer with multiple liver metastases: a case report.","authors":"Sifan Dong, Yunlong Gao, Zhe Wang, Jinqiang Liang, An Jiang","doi":"10.1007/s00432-025-06180-3","DOIUrl":null,"url":null,"abstract":"Background: Pancreatic cancer has a high degree of malignancy, poor prognosis, and short survival time. Surgical resection is the main treatment for pancreatic cancer, but the resection rate is only 20%. Liver metastases are the main reason of unresectable. The conversion therapy for pancreatic cancer with liver metastases is rare and less reported.Case presentation: A 52-year-old male patient with pancreatic cancer and multiple liver metastases was reported. Imaging examination showed multiple low-density shadows in the liver. Laboratory tests showed elevated levels of pro-gastrin-releasing peptide and CEA. After gemcitabine combined with albumin-bound paclitaxel chemotherapy, the liver metastases disappeared and the primary pancreatic head tumor was significantly reduced. Pancreaticoduodenectomy was performed, and the patient recovered well without any other adjuvant therapy. The patient has been alive for 36 months without tumor recurrence.Conclusions: The efficacy of Gemcitabine combined with Albumin-bound paclitaxel in conversion therapy for pancreatic cancer patients with multiple liver metastases may be related to the size and duration of metastases, which needs to be further studied.","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 7","pages":"200"},"PeriodicalIF":2.7000,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12226612/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cancer Research and Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00432-025-06180-3","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Pancreatic cancer has a high degree of malignancy, poor prognosis, and short survival time. Surgical resection is the main treatment for pancreatic cancer, but the resection rate is only 20%. Liver metastases are the main reason of unresectable. The conversion therapy for pancreatic cancer with liver metastases is rare and less reported.

Case presentation: A 52-year-old male patient with pancreatic cancer and multiple liver metastases was reported. Imaging examination showed multiple low-density shadows in the liver. Laboratory tests showed elevated levels of pro-gastrin-releasing peptide and CEA. After gemcitabine combined with albumin-bound paclitaxel chemotherapy, the liver metastases disappeared and the primary pancreatic head tumor was significantly reduced. Pancreaticoduodenectomy was performed, and the patient recovered well without any other adjuvant therapy. The patient has been alive for 36 months without tumor recurrence.

Conclusions: The efficacy of Gemcitabine combined with Albumin-bound paclitaxel in conversion therapy for pancreatic cancer patients with multiple liver metastases may be related to the size and duration of metastases, which needs to be further studied.

查看原文本刊更多论文

胰腺癌多发肝转移的转化治疗及R0切除1例报告。

背景：胰腺癌恶性程度高，预后差，生存时间短。手术切除是胰腺癌的主要治疗方法，但手术切除率仅为20%。肝转移是无法切除的主要原因。胰腺癌合并肝转移的转化治疗是罕见的，报道较少。病例介绍：我们报告了一位52岁男性胰腺癌合并多发性肝转移的病例。影像学检查示肝脏多发低密度影。实验室检查显示胃泌素释放前肽和CEA水平升高。吉西他滨联合白蛋白结合紫杉醇化疗后，肝转移灶消失，原发性胰头肿瘤明显减少。行胰十二指肠切除术后，患者恢复良好，无需其他辅助治疗。患者已存活36个月，肿瘤未复发。结论：吉西他滨联合白蛋白结合紫杉醇治疗胰腺癌多发肝转移的疗效可能与转移灶的大小和持续时间有关，有待进一步研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Cancer Research and Clinical Oncology 医学-肿瘤学

CiteScore

4.00

自引率

2.80%

发文量

577

审稿时长

2 months

期刊介绍： The "Journal of Cancer Research and Clinical Oncology" publishes significant and up-to-date articles within the fields of experimental and clinical oncology. The journal, which is chiefly devoted to Original papers, also includes Reviews as well as Editorials and Guest editorials on current, controversial topics. The section Letters to the editors provides a forum for a rapid exchange of comments and information concerning previously published papers and topics of current interest. Meeting reports provide current information on the latest results presented at important congresses. The following fields are covered: carcinogenesis - etiology, mechanisms; molecular biology; recent developments in tumor therapy; general diagnosis; laboratory diagnosis; diagnostic and experimental pathology; oncologic surgery; and epidemiology.